Optimind Pharma Corp. (CSE:OMND)

Optimind Pharma Income Statement

Financials in millions CAD. Fiscal year is March - February.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Feb 29, 2024	Feb 28, 2023	Feb 28, 2022
Revenue	0.12	0.17	0.1
Revenue Growth (YoY)	-27.72%	70.64%	-
Cost of Revenue	0.06	0.12	0.04
Gross Profit	0.06	0.05	0.06
Selling, General & Admin	0.51	0.92	0.44
Research & Development	0.12	-	-
Operating Expenses	0.81	0.96	0.47
Operating Income	-0.75	-0.91	-0.4
Interest Expense	-0.09	-0.07	-0.02
Other Non Operating Income (Expenses)	-0.21	-0.03	-
EBT Excluding Unusual Items	-1.05	-1.01	-0.42
Impairment of Goodwill	-	-0.86	-
Gain (Loss) on Sale of Investments	-	-0.31	-
Asset Writedown	-0.37	-0.65	-
Other Unusual Items	0.02	-0.26	-
Pretax Income	-1.41	-3.09	-0.42
Income Tax Expense	-0.01	-0.01	-0.14
Net Income	-1.4	-3.08	-0.28
Net Income to Common	-1.4	-3.08	-0.28
Shares Outstanding (Basic)	100	82	44
Shares Outstanding (Diluted)	100	82	44
Shares Change (YoY)	21.38%	88.09%	-
EPS (Basic)	-0.01	-0.04	-0.01
EPS (Diluted)	-0.01	-0.04	-0.01
Gross Margin	47.63%	30.49%	63.89%
Operating Margin	-612.59%	-533.41%	-405.39%
Profit Margin	-1136.63%	-1809.57%	-278.57%
EBITDA	-0.74	-0.89	-0.39
D&A For EBITDA	0.01	0.01	0.01
EBIT	-0.75	-0.91	-0.4

Source: S&P Global Market Intelligence. Standard template. Financial Sources.